- Home
- BWFG vs NGNE Comparison
BWFG vs NGNE Comparison
Compare BWFG & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BWFG | NGNE |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.0M | 327.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BWFG | NGNE |
|---|---|---|
| Price | $48.74 | $17.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $55.00 | $40.14 |
| AVG Volume (30 Days) | 32.0K | ★ 111.0K |
| Earning Date | 01-29-2026 | 03-23-2026 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | ★ 261.79 | N/A |
| EPS | ★ 4.45 | N/A |
| Revenue | ★ $107,283,000.00 | N/A |
| Revenue This Year | $17.64 | N/A |
| Revenue Next Year | $6.21 | N/A |
| P/E Ratio | $10.95 | ★ N/A |
| Revenue Growth | ★ 66.64 | N/A |
| 52 Week Low | $26.39 | $6.88 |
| 52 Week High | $51.54 | $37.27 |
Technical Indicators
Market Signals| Indicator | BWFG | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 51.75 | 45.19 |
| Support Level | $47.66 | $16.20 |
| Resistance Level | $49.98 | $17.95 |
| Average True Range (ATR) | 1.70 | 1.36 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 48.72 | 32.15 |
Price Performance
Historical ComparisonAbout BWFG Bankwell Financial Group Inc.
Bankwell Financial Group Inc is a bank holding company, engaged in providing financial products and services. It offers products related to commercial lending, retail lending, depository services, and others. The bank's commercial lending products includes owner-occupied commercial real estate loans, commercial real estate investment loans, commercial loans to small and mid-sized businesses and real estate construction and development loans. The retail lending products include residential mortgage loans, home equity lines of credit, and consumer installment loans. Its depository products include checking, savings, money market, certificates of deposit, noninterest-bearing demand, and time deposits.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.